$VANI News

Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update

Vivani Medical Q2 EPS $(0.07) Beats $(0.08) Estimate

Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026

Novo Nordisk signs pact with Vivani for long-lasting semaglutide implant

Novo Nordisk (CPSE:NOVO B) Teams Up With Vivani To Test A Semaglutide Implant

Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

Vivani strikes reverse-merger agreement with ClearOne for BCI business

Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management

Vivani Medical Receives Approval From Australian Human Research Ethics Committee Bellberry To Initiate SLIM-1, A Phase 1 Clinical Trial Of Semaglutide Implant NPM-139

Lake Street Initiates Coverage On Vivani Medical with Buy Rating, Announces Price Target of $4

Vivani Medical CEO Adam Mendelsohn to Present at the 2026 BIO International Convention

Vivani Medical CEO Adam Mendelsohn to Present at the Jefferies Global Healthcare Conference on June 4, 2026

Here's Why We're Watching Vivani Medical's (NASDAQ:VANI) Cash Burn Situation

Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update

Vivani Medical (VANI) Upgraded to Buy: What Does It Mean for the Stock?

Vivani Medical price target lowered to $3.50 from $4 at H.C. Wainwright

Vivani Medical Inc (NASDAQ:VANI) Reports Q4 2025 Results, Advances Semaglutide Implant to Phase 1

Vivani Medical: Q4 Earnings Snapshot

Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update